University of Michigan Pancreatic Cancer Center new partner in Immunovia’s global PANFAM-1 prospective validation study
LUND, Sweden, and Ann Arbor, USA ― Immunovia AB is pleased to announce that the University of Michigan Pancreatic Cancer Center has become the most recent member of the global network of prominent sites participating in the PANFAM-I prospective clinical study for the early diagnosis of pancreatic cancer in high risk individuals.Designed to validate Immunovia ́s blood test, IMMrayTMPanCan-d, the study will run for three years across clinical sites in both the US and Europe that are highly competent in screening programs of high risk pancreatic cancer patients. Pancreatic cancer has one of